Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Reuters Investment Profile
Provider: Sadif Analytics Prime
Provider: Wright Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Jiangsu Hengrui Medicine Co Ltd Announces Capital Injection into Subsidiary

Monday, 1 Apr 2013 08:00pm EDT 

Jiangsu Hengrui Medicine Co Ltd announced that the Company and 17 individuals including Sun Piaoyang and Jiang Xinhua, will respectively inject RMB 57.20 million and RMB 32.80 million into the Company's wholly owned subsidiary, a Chengdu-based pharmaceutical company. After that, the Company's holdings in the subsidiary will decrease to 67.2%.